Background:
The coupling of tissue engineering and controlled drug delivery technology with our efforts in growth factor biology have enabled us to contribute the clinical investigation of controlled release of angiogenic factors. Clinical trials are being supported to augment pre-clinical investigation of this promising mode of pharmacological treatment of obstructive vascular diseases and myocardial infarction.
Keywords:
Angiogenesis, neovascularization, myocardial ischemia, infarction
- Yu C, Cunningham M, Rogers C, Dinbergs ID, Edelman ER. The Biologic Effects of Growth Factor-Toxin Conjugates in Models of Vascular Injury Depend on Dose, Mode of Delivery, and Animal Species. Journal of Pharmaceutical Sciences. 1998 Nov. 87(11): 1300-1304. [PDF]
- Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic Angiogenesis with Basic Fibroblast Growth Factor: Technique and Early Results. Annals Thoracic Surgery. 1998. 65: 1540-1504. [PDF]
- Lopez J, Edelman E, Stamler A, Hibberd M, Prasad P, Caputo R, Carrozza J, Douglas P, Sellke F, Simons M. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters. Journal of Pharmacology and Experimental Therapeutics. 1997. 282(1): 385-390. [PDF]
| The PDF and files associated with the papers on this page are intended solely for the academic use of persons directly affiliated with the Edelman Laboratory. If you are not affiliated with the Laboratory, you are hereby notified that any downloading, copying, distribution or use of any of the PDF and files associated with the papers on this page is strictly PROHIBITED. |
|---|
77 Massachusetts Avenue, Building E25-438, Cambridge, MA 02139. USA.
Tel: 617-253-1569. Fax: 617-253-2514. E-mail: ere@mit.edu.
Copyright (C) 1998-2005 Massachusetts Institute of Technology. All rights reserved.
